References
- Vogler S , Zimmermann N , Leopold C , de Joncheere K . Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Rev. 2011; 4(2): 22–32.
- Vogler S . The impact of pharmaceutical pricing and reimbursement policies on generics uptake: Implementation of policy options on generics in 29 European countries–an overview. GaBi J. 2012; 1(2): 93–100.
- EUnetHTA. http://www.eunethta.eu/ [cited 22 August 2012]..
- Gilabert A , Mueller T , Bouslouk M , Toumi M . Managing uncertainty: The new way forward for market access. 2013. Workshop, ISPOR Europe, Dublin, 2–6 November.
- Toumi M , Mueller T . From decision point to decision window: readiness for a change of paradigm. Workshop, ISPOR Europe, Berlin, 3–7 November. 2012
- Thiébaut SP , Barnay T , Ventelou B . Ageing, chronic conditions and the evolution of future drugs expenditure: A five-year micro-simulation from 2004 to 2029. Applied Eco. 2013; 45(13): 1663–72.
- Connor P , Alldus C , Ciapparelli C , Kirby L . Long Term Pharmaceutical Forecasting: IMS Health’s Experience. Journal of Business Forecasting Methods & Systems. 2003; 22(1): 10.
- Keehan SP , Sisko AM , Truffer CJ , Poisal JA , Cuckler GA , Madison AJ et al. . National health spending projections through 2020: Economic recovery and reform drive faster spending growth. Health Affairs. 2011; 30(8): 1594–605.
- Wettermark B , Persson ME , Wilking N , Kalin M , Korkmaz S , Hjerndahl P et al. . Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res. 2010; 10: 128.
- Generics and Biosimilars Initiative (GaBi). US$67 billion worth of biosimilar patents expiring before 2020. 2012. Available from: http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020 [cited 22 August 2012]..
- European Medicines Agency (EMA). Central authorization of medicines. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000109.jsp [cited 10 October 2013].
- European Commission. Pharmaceutical sector inquiry. Final Report. 2009. Available from: http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/staff_working_paper_part1.pdf [cited 10 October 2013].
- DiMasi JA , Feldman L , Seckler A , Wilson A . Trends in risks associated with new drug development: Success rates for investigational drugs. Int J Clin Pharmacol Therapeut. 2010; 87: 272–77.
- European Commission. The 2012 ageing report-Economic and budgetary projection for the 27 EU Member States (2010–2060). 2012; 2. Available from: http://ec.europa.eu/economy_finance/publications/european_economy/2012/pdf/ee-2012r-2_en.pdf [cited 10 October 2013] Eur Econ.
- Urbinati D , Rémuzat C , Kornfeld Å , Vataire AL , Cetinsoy L , Aballéa S et al . EU Pharmaceutical expenditure forecast. JMAHP. 2014; 2: 23738.